Reevaluating the role of direct oral anticoagulants in cardiovascular treatment

Direct oral anticoagulants (DOACs) are a common treatment for patients with a wide variety of cardiovascular conditions.

Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers – Pharmaceutical Technology

20mg/ml injections of Bizengri will be available to patients in coming weeks. Credit: aslysun / Shutterstock. Merus’ Bizengri (zenocutuzumab-zbco) has received accelerated approval from the

December 7, 2024

Ascendis spins out ophthalmology company; Gamida Cell eyes strategic options

Plus, news about Skye Bioscience and Vera Therapeutics: Ascendis Pharma, investors spin out eye care company: Eyconis, based in Redwood City, CA, will develop, manufacture

January 30, 2024

High ADHD Medication Doses Tied to Psychosis; Rapid Tests for Malaria

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange,

September 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.